Full Text
EE506 Clinical Consequences and Associated Costs of Treating Patients With Waldenström Macroglobulinemia in the First-Line Setting With Bruton Tyrosine Kinase Inhibitors

Abstract

Authors

S Crawford H Li M Salkar X Yu P Martin

Back to Volume 27, Supplemental Issue 6S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×